



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM
TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tárgynév: **Financing of health technologies**
Tárgykód: **HCP213**
Tárgyfelelős neve: **Kaló Zoltán Dr.**
Tárgy követelménye: **Kollokvium (5)**
Tárgy heti óraszám: **3/0/0**

Oktatás célja:

Place in the time-schedule: 3rd semester
Faculty: András Inotai, Péter Arányi, Marcell Csanádi
Responsible lecturer: András Inotai PhD, DrHabil

Tantárgy tartalma:

Themes

Date	Theme	L e c t u r e r	Literature	Additional literature
------	-------	--------------------------------------	------------	-----------------------



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM
TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

02. 13	12.00 13.30 (0.10 0A)	Transpa rency Directiv e / Principl es META/ ISPOR	Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en:HTML	Kolasa K, Kalo Z, Zah V, Dolezal T. The role of HTA in the process of implementation of EU Transparency Directive: a relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 2012 12. 3. 283-7.
02. 20	12.00 13.30 (0.10 0A)	Risk sharing (theory)	Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013. 16(5). 703-19.	Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015. 124. 39-47



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM

TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

02. 27	12.00 I. 13.30 (0.99)	Risk-sharing (Computer room)		
03. 06	12.00 II. 13.30 (0.99)	Risk-sharing (Computer room)		
03. 13	12.00 13.30 (0.10 OA)	Generic drug policies	Kalo Z, Abonyi-Toth Zs, Bartfai Z, Voko Z: Pitfalls associated with the therapeutic reference pricing practice of asthma medication, BMC Pulmonary Medicine, 2012 20. 12. 1. 35; 48. Kaló Z, Holtorf AP, Alonso R, Shen J, Ágh T, Inotai A, Brixner D. Need for multi-criteria evaluation of generic drugs policies. Value in Health. 2015	Kaló Z, Muszbek N, Bodrogi J, Bidló J: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence, Health Policy, 2007. 80. 3. 402-12.



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM

TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

03. 20	12.00 13.30 (0.10 0A)	Biosimilar drug policies	Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z (2018). Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International. DOI: 10.1155/2018/9597362 Inotai A, Csanádi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P, Kaló Z (2017). Policy practices to maximise social benefit from biosimilars. Journal of Bioequivalence & Bioavailability. 9:467-472. DOI:10.4172/jbb.1000346	GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market http://www.egagenerics.com/images/Website/GfK_Final_Report_Factors_Supporting_a_Sustainable_European_Biosimilar_Medicines_Market.pdf
03. 27	12.00 13.30 (0.10 0A)	External price referencing	Csanádi M, Kaló Z, Prins CPJ, Grélinger E, Menczelné Kiss A, Fricke FU, Fuksa L, Tesar T, Manova M, Lorenzovici L, Vokó L, Garrison LP. The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology. 2018. 7(3): 243-250	Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res, 2013. 13. 6. 735-741.



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM
TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

04. 03	12.00 - 13.30 (0.10 0A)	Cost- contain ment policies	Carone G, Schwierz C, Xavier A. Cost- containment policies in public pharmaceutical spending in the EU. Economic Papers 461. 2012 http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf	
04. 10	12.00 - 13.30 (0.10 0A)	Financi ng research h of new health technol ogies		
04. 24	12.00 13.30 (0.10 0A)	Financi ng hospital technol ogies		



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM

TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

05. 08	12.00 13.30 (0.10 0A)	GROUP PRESEN TATION		
-----------	--------------------------------	---------------------------	--	--



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM
TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Tantárgy tartalma:

05.15	12.00 13.30 (0.10 0A)	Summary		

Számonkérési és értékelési rendszere:

Assignments (100 points)

- Risk-sharing exercise of an Osteoporosis product (60 points)
-

Task	Prepare 5 different risk sharing scenarios in a health economic model for an OP product (Excel model will be provided for you)
Type of assignment	Team Work – up to 4 students/team
Expected deliverables	Presentation (20p) • Slide deck (5 slides for each risk sharing techniques, 2 slides for discussion) Model + report (40 p) (Evaluated by Anett Molnár) • Model report (3 to 4 pages, if more than 4, the first 4 pages will be reviewed) • Each risk sharing scenario evidenced by an adjusted excel model (one excel for each scenario)
Deadlines for deliverables	27th April (report, models scenarios and slide deck), 7th May (presentation slides) Presentation will be at 8th May
Comments	



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM

TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Számonkérési és értékelési rendszere:

- Writing an essay (40 points)
-

Task	Prepare an essay entitled: Financing biologic products in a selected country – current situation, challenges and future perspectives
Type of assignment	Team Work – up to 4 students/team
Expected deliverables	Essay between 4 to 6 pages (if more than 6, the first 6 pages will be reviewed), with 30 peer reviewed scientific papers in the reference list
Deadlines	11th May
Comments	You may choose ANY country, besides 1) country of anybody from the team 2) Hungary Recommendation: to maximize your scores, try to utilize information (e.g. classes on cost containment, external price referencing, risk sharing, biosimilar drug policy etc.) from as many classes of the module, as possible! The key objective of this submission is to see how students can integrate their knowledge in a policy essay. TIPP: After attending each class, think and make notes about how the topic could be channeled to the essay.

Points	grades
89 – 100:	5
76 – 88:	4
63 – 75:	3
50 – 62:	2
below 50:	1

Attendance: one absense is permitted



Tárgytematika

EÖTVÖS LORÁND TUDOMÁNYEGYETEM

TÁTK Egészségpolitika és Egészség-gazdaságtan Tanszék
(TÁTK-EGPOL-TANSZ)

2019/20/2

Kötelező irodalom:

- Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en:HTML>
- Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. *Value Health*. 2013. 16(5). 703-19.
- Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. *Economic Papers* 461. 2012
http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
- Kalo Z, Abonyi-Toth Zs, Bartfai Z, Voko Z: Pitfalls associated with the therapeutic reference pricing practice of asthma medication, *BMC Pulmonary Medicine*, 2012 20. 12. 1. 35; 48.
- Kaló Z, Holtorf AP, Alonso R, Shen J, Ágh T, Inotai A, Brixner D. Need for multi-criteria evaluation of generic drugs policies. *Value in Health*. 2015
- Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z (2018). Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. *BioMed Research International*. DOI: 10.1155/2018/9597362
- Inotai A, Csanádi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P, Kaló Z (2017). Policy practices to maximise social benefit from biosimilars. *Journal of Bioequivalence & Bioavailability*. 9:467-472. DOI:10.4172/jbb.1000346
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. *Expert Rev Pharmacoecon Outcomes Res*, 2013. 13. 6. 735-741.